Ad is loading...
RNA
Price
$43.65
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
103 days until earnings call
VINC
Price
$0.28
Change
-$0.00 (-0.00%)
Updated
Nov 20 closing price
131 days until earnings call
Ad is loading...

RNA vs VINC

Header iconRNA vs VINC Comparison
Open Charts RNA vs VINCBanner chart's image
Avidity Biosciences
Price$43.65
Change-$0.00 (-0.00%)
Volume$675.47K
CapitalizationN/A
Vincerx Pharma
Price$0.28
Change-$0.00 (-0.00%)
Volume$205.06K
CapitalizationN/A
RNA vs VINC Comparison Chart
Loading...
RNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VINC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
RNA vs. VINC commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNA is a Hold and VINC is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (RNA: $43.65 vs. VINC: $0.28)
Brand notoriety: RNA and VINC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNA: 51% vs. VINC: 30%
Market capitalization -- RNA: $5.21B vs. VINC: $9.16M
RNA [@Biotechnology] is valued at $5.21B. VINC’s [@Biotechnology] market capitalization is $9.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $458.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNA’s FA Score shows that 0 FA rating(s) are green whileVINC’s FA Score has 1 green FA rating(s).

  • RNA’s FA Score: 0 green, 5 red.
  • VINC’s FA Score: 1 green, 4 red.
According to our system of comparison, both RNA and VINC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNA’s TA Score shows that 4 TA indicator(s) are bullish while VINC’s TA Score has 5 bullish TA indicator(s).

  • RNA’s TA Score: 4 bullish, 6 bearish.
  • VINC’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, VINC is a better buy in the short-term than RNA.

Price Growth

RNA (@Biotechnology) experienced а -16.86% price change this week, while VINC (@Biotechnology) price change was -14.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.72%. For the same industry, the average monthly price growth was -7.79%, and the average quarterly price growth was +1.74%.

Reported Earning Dates

RNA is expected to report earnings on Mar 04, 2025.

VINC is expected to report earnings on Apr 01, 2025.

Industries' Descriptions

@Biotechnology (-3.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($5.08B) has a higher market cap than VINC($8.59M). RNA YTD gains are higher at: 382.320 vs. VINC (-76.644). VINC has higher annual earnings (EBITDA): -27.1M vs. RNA (-322.04M). RNA has more cash in the bank: 1.59B vs. VINC (10.1M). VINC has less debt than RNA: VINC (1.64M) vs RNA (7.6M). RNA has higher revenues than VINC: RNA (10.1M) vs VINC (0).
RNAVINCRNA / VINC
Capitalization5.08B8.59M59,115%
EBITDA-322.04M-27.1M1,188%
Gain YTD382.320-76.644-499%
P/E RatioN/AN/A-
Revenue10.1M0-
Total Cash1.59B10.1M15,733%
Total Debt7.6M1.64M464%
TECHNICAL ANALYSIS
Technical Analysis
RNAVINC
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
RNA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VINC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JPUS120.090.47
+0.39%
JPMorgan Diversified Return US Eq ETF
FDNI28.640.06
+0.21%
First Trust Dow Jones Intl Intnt ETF
IGLD21.360.04
+0.19%
FT Cboe Vest Gold Strategy Trgt Inc ETF
AIQ38.190.04
+0.10%
Global X Artfcl Intlgc & Tech ETF
IPOS12.22-0.09
-0.72%
Renaissance International IPO ETF

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
+0.92%
DYN - RNA
47%
Loosely correlated
+1.04%
RXRX - RNA
41%
Loosely correlated
-3.67%
ACLX - RNA
41%
Loosely correlated
-0.42%
VCYT - RNA
40%
Loosely correlated
+0.13%
ALEC - RNA
39%
Loosely correlated
-5.58%
More

VINC and

Correlation & Price change

A.I.dvisor indicates that over the last year, VINC has been loosely correlated with INKT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if VINC jumps, then INKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VINC
1D Price
Change %
VINC100%
+0.99%
INKT - VINC
39%
Loosely correlated
+2.61%
APVO - VINC
33%
Loosely correlated
+16.05%
RNA - VINC
31%
Poorly correlated
+0.92%
VNDA - VINC
30%
Poorly correlated
-0.41%
IOVA - VINC
30%
Poorly correlated
-0.61%
More